Beta-lactam

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Retrieved on: 
Tuesday, April 9, 2024
Colistin, Beta-lactam, Education, Development, Partnership, Patient, HHS, Gram-negative bacteria, Escherichia coli, World Health Organization, Infection, USD, Administration, Antibiotic, BMBF, Pharmaceutical industry

The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis.

Key Points: 
  • The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis.
  • Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project achieves certain milestones.
  • The program comprises antibiotics targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria.
  • The molecules belong to one of the very few novel classes of antibiotics in development.

Labroots Announces Agenda for its 7th Annual Drug Discovery & Development Virtual Event on February 21, 2024

Retrieved on: 
Thursday, February 15, 2024
Neuroscience, Toxicity, Doctor of Philosophy, FCCP, Lactation, FCP, Spectrum, Fear, Labroots, Associate, Anxiety, Networking hardware, Oxytocin, G protein-coupled receptor, Tumor microenvironment, QIAGEN, Drug discovery, Therapy, Digital image, DSM-IV codes, Thermo Fisher Scientific, Advantage Business Media, Laboratory, Miltenyi Biotec, Doctor of Pharmacy, MPS, Safety, Biomarker, Beta-lactam, Sartorius, Regulation, Master of Science, Merck, Epithelial–mesenchymal transition, Dean (education), Lung cancer, Cancer, Pharmaceutical industry

YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series. Hosted on February 21st and free to attend, attendees will experience the forefront of pharmaceutical innovation joining industry and academic leaders from around the world debating the latest, insightful scientific breakthroughs in this ever-evolving field.

Key Points: 
  • Focusing from pre-clinical development to clinical development, advances in the field of drug discovery and development will be explored shaping current and future challenges in drug research
    YORBA LINDA, Calif., Feb. 15, 2024 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual and hybrid events and webinars, today announced its 7th annual event in the Drug Discovery & Development Virtual Event Series .
  • The 2024 informative agenda covers a range of sessions spanning areas including Emerging Modalities in Drug Discovery and Preclinical Development, New Methods in Pharmacogenomics, and Biomarker Applications.
  • Use the hashtag #LRdrug to follow the conversation and connect with other members of the global Drug Discovery & Development community!
  • Follow @DrugDiscoveryLR on Twitter and @DrugDiscoveryandDevelopment on Facebook to connect with our specialist Drug Discovery & Development writers and stay up to date with the latest Trending News in Drug Discovery & Development.

Basilea announces acquisition of preclinical antibiotics program from Spexis

Retrieved on: 
Monday, January 15, 2024
Escherichia coli, World Health Organization, Patient, Gram-negative bacteria, Colistin, Partnership, Beta-lactam, Infection, Transmembrane protein, Bacteria, Klebsiella, Intellectual property, CHF, Lipopolysaccharide, Klebsiella pneumoniae, Vaccine

We are excited by the addition of this new program to our growing pipeline and to continue the development of this targeted antibiotics class, which has the potential to address an unmet medical need in the treatment of severe bacterial infections in the hospital.”

Key Points: 
  • We are excited by the addition of this new program to our growing pipeline and to continue the development of this targeted antibiotics class, which has the potential to address an unmet medical need in the treatment of severe bacterial infections in the hospital.”
    The antibiotics were developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program and selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria.
  • This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria.
  • The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator).2 This underscores the potential of this novel class of antibiotics.
  • In addition, Basilea assumes the rights and obligations of Spexis, including potential low single-digit percentage royalties on sales, under licensing agreements.

Resistance to antibiotics in northern Nigeria: what bacteria are prevalent, and which drugs work against them

Retrieved on: 
Sunday, September 17, 2023
Gaps, Infection, Multidrug-resistant bacteria, Tetracycline, Antimicrobial stewardship, Physician, Antimicrobial spectrum, Hospital, Centers for Disease Control and Prevention, Whole genome sequencing, Urinary tract infection, Aminoglycoside, Drug resistance, Death, Patient, Laboratory, Time, Blood, Gene, Stockholm Environment Institute US Center, Beta-lactam, Bacteria, Tigecycline, News, Fosfomycin, Family, Antibiotics, Food preservation, Pharmaceutical industry, Vaccine

Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.

Key Points: 
  • Antimicrobial resistance – the ability of microorganisms to resist drugs that have been developed to control them – is a severe problem in African countries.
  • The continent has the highest global burden of antimicrobial-resistant infections, with 114.8 deaths per 100,000 people.
  • Physicians need laboratory data to choose the right antibiotic, at the right dose, for the right period of time.
  • This can lead to choosing ineffective antibiotics, which can lead to increases in resistant bacteria.
  • In other words, to develop a list of what bacteria are prevalent in the region and which drugs work against them.
  • To accomplish this, we recently conducted a study of multidrug-resistant bacteria obtained from patients in six hospitals in northern Nigeria.

Drug-resistant bacteria in Nigeria

    • We chose to analyse bacteria that are resistant to more than one drug because they are the biggest challenge when treating infections.
    • We found that about 85% of the bacteria isolated from infections were resistant to the most commonly used antibiotics.
    • The good news was that two antibiotics, tigecycline and fosfomycin, remained very active even against highly resistant strains of bacteria.

Genetic mechanisms

    • This was done to understand what made these organisms so resistant to antibiotics at the molecular level.
    • The data revealed an astonishingly high number of genetic mechanisms making the microorganisms resistant.
    • In some cases, the genetic information encoding resistance was capable of being shared among other microorganisms.

The need for antimicrobial stewardship

    • Some of the resistance genes were capable of moving from one microorganism to another (mobile resistance genes).
    • Antimicrobial stewardship based on laboratory data is effective especially if done locally, regionally and nationally.

Antimicrobial resistance is everyone’s concern

    • Read more:
      Antimicrobial resistance calls for brainpower of a space agency and campaigning zeal of an NGO

      Fourth, there are things that everyone can do to help bring antibiotic resistance under control.

    • For example, the US Centers for Disease Control and Prevention list five things that everyone should know about drug resistance and 10 activities to protect yourself and your family against resistance.
    • He is affiliated with the International Society for Antimicrobial Chemotherapy.

Shionogi’s Innovative Antibiotic, FETCROJA® (cefiderocol), Is Now Available in Norway

Retrieved on: 
Wednesday, January 18, 2023
Pharmaceutical, Health, Clinical Trials, Animal, Infection, News, Cell, Engine Company 21 (Chicago), World Health Organization, COVID-19, AMR, WHO, Microbiology Society, AMPC, Beta-lactam, Penicillin-binding proteins, National Strategy to Secure Cyberspace, Pseudomonas aeruginosa, Bacteria, Vaccine, CR, Death, Patient, Research, Mortality, Stenotrophomonas maltophilia, Enzyme, Human, Gram-negative bacteria, Esbly, Cefiderocol, European Commission, Alliance Healthcare, Pharmaceutical industry, Distribution (marketing), Antibiotics, Shionogi

Since its European Commission approval in 2020, over 23,000 patients in total have now been treated with cefiderocol throughout Europe.

Key Points: 
  • Since its European Commission approval in 2020, over 23,000 patients in total have now been treated with cefiderocol throughout Europe.
  • Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years.
  • Shionogi is proud to be one of the few large pharmaceutical companies that continues to focus on research and development in anti-infectives.
  • The company invests the highest proportion of its pharmaceutical revenues in relevant anti-infectives R&D compared to other large pharmaceutical companies.21

InsightRX to Showcase Precision Dosing Technology at ASHP 2022 Midyear Meeting

Retrieved on: 
Thursday, December 1, 2022
Antifungal, Mandalay Bay Convention Center, Doctor of Philosophy, Voriconazole, Patient, SAN, Beta-lactam, Anticoagulant, Nephrotoxicity, Literature, Pharmacokinetics, Machine learning, Risk, Patient safety, Exhibition, Health, Mortality, Magnetic resonance, Vancomycin, Toxicity, Ambiguity, BCPS, Pharmacist, Society, Senior, Tacrolimus, Nova, Doctor of Pharmacy, Precision medicine, ASHP, Infection, Pharmacy management system, Forecasting, Customer experience, AUC, Pharmaceutical industry, Medical imaging

SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX — which provides cloud-based precision dosing support to guide treatment decisions – announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.

Key Points: 
  • SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- Today, InsightRX which provides cloud-based precision dosing support to guide treatment decisions announced its slate of activities and demonstrations during the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting and Exhibition in Las Vegas from Dec. 4-8.
  • At ASHP Midyear, held at the Mandalay Bay Convention Center, they will be showcasing several new therapeutic categories that are now a part of their offering.
  • 2020 brought the newest vancomycin consensus guidelines ,which firmly recommended Bayesian forecasting software as the preferred method of dosing and monitoring.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

InsightRX to Showcase New Advances in Precision Dosing Technology During IDWeek 2022

Retrieved on: 
Wednesday, October 19, 2022
SAN, Doctor of Pharmacy, Infection, Thought, Customer experience, Conference, Machine learning, Reiki, Aminoglycoside, Berufsgenossenschaftliche Kliniken Bergmannstrost Halle, AKI, Learning, Senior, Precision medicine, Acute kidney injury, New, Convention center, CEO, Beta-lactam, Health, BCPS, EDT, AUC, Product, Vancomycin, Anticoagulant, Pharmaceutical industry, Pharmacy

SAN FRANCISCO, Oct. 19, 2022 /PRNewswire/ -- Today, InsightRX -- which provides cloud-based precision dosing support to guide treatment decisions – announced its slate of activities and presentations during the upcoming IDWeek™2022 Conference (Walter E. Washington Convention Center in Washington, D.C., Oct. 19 – 23). 

Key Points: 
  • InsightRX will exhibit and provide demonstrations of how Model-Informed Precision Dosing is improving patient care and helping hospital bottom lines during IDWeek's IDExpo ( Hall A, Booth #103 of the convention center).
  • 2022 has been a year of accelerated innovation for InsightRX, which is expanding its platform to include solid organ transplant drugs and anticoagulants.
  • InsightRX will showcase advances specifically in infectious disease areas during an IDWeek Learning Lounge presentation:
    The New ABCs Of Model-Informed Precision Dosing: Antifungals, Beta-lactams, and Model-Informed Continuous LearningJon Faldasz, PharmD, BCPS, Senior Director of Product & Customer Experience at InsightRX, will discuss how model-informed precision dosing is being applied to new therapeutic areas.
  • InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analytics designed to individualize treatment at the point of care.

Qpex Biopharma Announces Presentations on Phase 1 and Nonclinical Data on Three Clinical Stage Oral and IV Products Targeting Antibiotic-Resistant Bacterial Infections at 2022 ID Week Meeting

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, LinkedIn, Doctor of Pharmacy, CDC, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Office of Inspector General, U.S. Department of Health and Human Services, PD, Society of Infectious Diseases Pharmacists, Infection, Biopharma LLC, Pharmacist, Twitter, Partnership, WHO, BARDA, World, Acinetobacter, Acinetobacter baumannii, Aivo Orav, Society, Pseudomonas aeruginosa, Health, PIDS, OTA, Infectious Diseases Society of America, Beta-lactam, World Health Organization, Lipopeptide, IDSA, Pharmacokinetics, Drug of last resort, ID, ESBL, Pharmaceutical industry, Hospital, Tolerability, Pseudomonas, FIDSA, Safety

Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.

Key Points: 
  • Qpex Biopharma today announced that clinical and preclinical data on its portfolio of clinical stage investigational antibiotic programs will be featured in several presentations at the upcoming 2022 ID Week Meeting in Washington, DC on October 19-23.
  • The presentations will describe progress on three Qpex investigational products that the recent WHO pipeline analysis identified as addressing drug-resistant pathogens for which there is a critical need for new drugs.
  • QPX9003: a next-generation, IV-administered synthetic lipopeptide with an enhanced therapeutic profile designed to focus on highly drug-resistant infections caused by Pseudomonas and Acinetobacter.
  • The company also has a partnership with Brii Biosciences for the development and commercialization of three of its products in greater China.

SHIONOGI SIGNS AGREEMENT WITH NHS ENGLAND TO BEGIN AN INNOVATIVE SUBSCRIPTION PAYMENT MODEL FOR REIMBURSEMENT OF ITS ANTIBIOTIC, FETCROJA®▼ (CEFIDEROCOL)

Retrieved on: 
Wednesday, June 15, 2022
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology, Penicillin-binding proteins, CNS, World, Degenerative disease, BSI, Infection, Death, Gastroenterology, Central nervous system disease, Gram-negative bacteria, NHS, AMR, Sepsis, VAP, Research, Stenotrophomonas maltophilia, Beta-lactam, CR, Marketing, Subclinical infection, Pain, Pseudomonas aeruginosa, Health, Intention, World Health Organization, SVP, Multidrug-resistant bacteria, Medicine, Patient, The Problem of Cell 13, NICE, Cell, HAP, NHS England, Antibiotics, Pharmaceutical industry, Risk management, Vaccine, Shionogi, Cefiderocol

Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), today announced that Shionogi B.V. had signed an agreement with NHS England to begin an innovative subscription payment model reimbursement of Cefiderocol in England.

Key Points: 
  • Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), today announced that Shionogi B.V. had signed an agreement with NHS England to begin an innovative subscription payment model reimbursement of Cefiderocol in England.
  • Once launched, there is often a low frequency of use driven by the need for stewardship to prevent resistance development.
  • Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years.
  • Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit www.shionogi.eu .

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

Retrieved on: 
Thursday, February 10, 2022
Adoption, Nadine Opgen-Rhein, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Private Securities Litigation Reform Act, Goal, Precision medicine, Technology, Public health, Gene, COVID-19, Gram-negative bacteria, Whole genome sequencing, AST, Aminoglycoside, Drug resistance, Journal, Beta-lactam, Enterococcus faecalis, Lancet, NGS, PPA, Infection, Securities Act of 1933, Culture, Antibiotic sensitivity testing, Infectious Diseases Society of America, WGS, Drug of last resort, Nasdaq, Pseudomonas aeruginosa, Detection, GLOBE, European Journal of Clinical Microbiology & Infectious Diseases, Bacteria, AMR, NPA, Informatics, Colistin, Solution, Security (finance), Securities Exchange Act of 1934, Fatality, FDA, Hospital, IDSA, Vaccine, MD, Enterobacterales

The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing (WGS), organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture.

Key Points: 
  • The Acuitas AMR Gene Panel results were compared with a combined reference standard including whole genome sequencing (WGS), organism identification and phenotypic antimicrobial susceptibility testing using standard of care microbiology culture.
  • In this publication titled Multicenter Evaluation of the Acuitas AMR Gene Panel for Detection of an Extended Panel of Antimicrobial Resistance Genes among Bacterial Isolates 1, the authors note that associating the AMR markers with not susceptible phenotypic results is a key differentiator of the FDA-cleared Acuitas AMR Gene Panel compared to other molecular panels that simply detect the presence or absence of a gene.
  • Several clinical cases illustrating the potential utility of the Acuitas AMR Gene Panel were presented during a recent webinar titled Discovering the FDA-cleared Acuitas AMR Gene Panel: Building a Case for Clinical Utility .
  • This press release includes statements regarding the publication of results of a recent study of the Acuitas AMR Gene Panel.